Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 11/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 0.86 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.75 |
| ▸ | NPC1 | O15118 | 3/20 | 0.74 |
| ▸ | RAB9A | P51151 | 3/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.72 |
| ▸ | NPY1R | P25929 | 1/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.70 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20748052 | 0.98 | LTA4H (0.97) | LTA4HHTTHRH3NPC1RAB9A | |
| SCHEMBL4688871 | 0.98 | LTA4H (0.97) | LTA4HHTTHRH3NPC1RAB9A | |
| SCHEMBL4689454 | 0.92 | KDM4E (0.86) | LTA4HHTTHRH3NPC1RAB9A | |
| SCHEMBL3581020 | 0.91 | NPC1 (0.87) | LTA4HHTTHRH3NPC1RAB9A | |
| SCHEMBL14970586 | 0.91 | NPC1 (0.87) | LTA4HHTTHRH3NPC1RAB9A | |
| SCHEMBL7402238 | 0.89 | KDM4E (0.85) | LTA4HHTTHRH3NPC1RAB9A | |
| SCHEMBL7402377 | 0.88 | KDM4E (0.85) | LTA4HHTTHRH3NPC1RAB9A | |
| SCHEMBL7400511 | 0.88 | KDM4E (0.85) | LTA4HHTTHRH3NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL7397479 | 0.88 | KDM4E (0.82) | LTA4HHTTHRH3NPC1RAB9A | |
| SCHEMBL7399833 | 0.88 | KDM4E (0.85) | LTA4HHTTHRH3NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10981887-B2 | Benzothiophene estrogen receptor modulators | G1 THERAPEUTICS, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200216406-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS | G1 THERAPEUTICS, INC. (US) | 2020-07-09 | — | — | US | disclosed |
| US-10633362-B2 | Benzothiophene estrogen receptor modulators | G1 THERAPEUTICS, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20190119243-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS | G1 THERAPEUTICS, INC. (US) | 2019-04-25 | — | — | US | disclosed |
| US-10208011-B2 | Benzothiophene estrogen receptor modulators | G1 THERAPEUTICS, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| EP-2373163-B1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2015-06-10 | — | — | EP | disclosed |
| EP-2373163-B1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2015-06-10 | — | — | EP | disclosed |
| US-8232273-B2 | Heterocyclic compounds and methods of use | GENENTECH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232273-B2 | Heterocyclic compounds and methods of use | GENENTECH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232273-B2 | Heterocyclic compounds and methods of use | GENENTECH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-6506876-B1 | LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use | G.D. SEARLE & CO. | 2003-01-14 | — | — | US | disclosed |
| EP-0804427-B1 | LTA4 HYDROLASE INHIBITORS | SEARLE & CO (US) | 2002-09-18 | — | — | EP | disclosed |
| EP-1221441-A2 | LTA4 Hydrolase inhibitors | G.D. SEARLE & CO. (US) | 2002-07-10 | — | — | EP | disclosed |
| US-5723492-A | LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use | G.D. SEARLE & CO. (US) | 1998-03-03 | — | — | US | disclosed |
| US-5719306-A | ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1998-02-17 | — | — | US | disclosed |
| EP-0804427-A1 | LTA4 HYDROLASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-11-05 | — | — | EP | disclosed |
| EP-0786992-A2 | LTA 4? HYDROLASE INHIBITOR PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | G.D. SEARLE & CO. (US) | 1997-08-06 | — | — | EP | disclosed |
| US-5585492-A | USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES WHICH ARE MEDIATED BY LTB4 PRODUCTION, SUCH AS PSORIASIS, ULCERATIVE COLITIS, IRRITABLE BOWEL DISEASE AND ASTHMA | G. D. SEARLE & CO. (US) | 1996-12-17 | — | — | US | disclosed |
| WO-1996010999-A2 | LTA4 HYDROLASE INHIBITOR PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | G.D. SEARLE & CO. (US) | 1996-04-18 | — | — | WO | disclosed |
| WO-1996011192-A1 | LTA4 HYDROLASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981887-B2 | Benzothiophene estrogen receptor modulators | ESR1, GPER1, ESR2 | LTA4H 2170/4885HTT 1106/4885HRH3 2487/4885 |
| US-10208011-B2 | Benzothiophene estrogen receptor modulators | ESR1, GPER1, ESR2 | LTA4H 2170/4885HTT 1106/4885HRH3 2487/4885 |
| US-20200216406-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS | ESR1, GPER1, ESR2 | LTA4H 2170/4885HTT 1106/4885HRH3 2487/4885 |
| US-10633362-B2 | Benzothiophene estrogen receptor modulators | ESR1, GPER1, ESR2 | LTA4H 2170/4885HTT 1106/4885HRH3 2487/4885 |
| US-20190119243-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS | ESR1, GPER1, ESR2 | LTA4H 2170/4885HTT 1106/4885HRH3 2487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.